Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Genzyme/Bayer Report Positive Top-Line Phase II MS Data For Campath

Oct 15 2007

• By Shirley Haley

Related Content

Biogen Idec/Elan Report Positive Two-Year Tysabri Follow-On Data

Oct 12 2007

Genzyme Initiates Campath Phase III Study In Multiple Sclerosis

Sep 26 2007

Genzyme’s Campath MS Safety Profile Expected From FDA By July; Phase III Set For Second Half

May 19 2006

Elan/Biogen Idec's Tysabri, Formerly Antegren, Approved For MS Based On One-Year Data

Nov 23 2004

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.